US 2011 0052718A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0052718A1 Rangel (43) Pub. Date: Mar. 3, 2011 (54) SYNERGISTIC PHYTOCEUTICAL A6IR 36/4I (2006.01) COMPOSITIONS A636/7 (2006.01) A636/74 (2006.01) (76) Inventor: José Angel Olalde Rangel, Caracas A636/734 (2006.01) (VE) A6IR 36/45 (2006.01) A6II 35/32 (2006.01) (21) Appl. No.: 12/942,766 A6IP 9/00 (2006.01) A6IP5/00 (2006.01) (22) Filed: Nov. 9, 2010 A6IP 700 (2006.01) Related U.S. Application Data (52) U.S. Cl. .................................... 424/549; 424/195.15 (60) Division of application No. 1 1/271,940, filed on Nov. (57) ABSTRACT 10, 2005, now Pat. No. 7,303,772, Continuation of Phytoceutical compositions for the prevention and treatment application No. 12/705,525, filed on Feb. 12, 2010. of circulatory disorders, feminine endocrine disorders, and O O dermal disorders. A specific combination of extracts of plants Publication Classification is taught, as well as principles for varying the formulations (51) Int. Cl. based on categorizing plants into one of three groups, Energy, A6 IK 36/074 (2006.01) Bio-Intelligence, and Organization and selecting several A6 IK 36/258 (2006.01) plants from each group. Such combinations have synergistic A6 IK 36/28 (2006.01) effects, with minimal side effects. riographic eficience afiabetic rati remissists, irreiraig fest of treatast aetgees hairs. appier trasound se Patent Application Publication Mar. 3, 2011 Sheet 1 of 3 US 2011/0052718A1 fisiae : yesigraisie eitiece 3 filiateig cit reasissists, it airig eigth of treatifier eater ghatas. Doppler Ultrascard e Patent Application Publication Mar. 3, 2011 Sheet 2 of 3 US 2011/0052718A1 Figure 2: Ficts before after echosartographic carnparisor. Enterval between echesonagraris is a trants sia's ser Patent Application Publication Mar. 3, 2011 Sheet 3 of 3 US 2011/0052718A1 Figure 3: Photographic eviderace of severe Psoriasis rentissions, including ength of treatenter between photos US 2011/0052718A1 Mar. 3, 2011 SYNERGISTC PHYTOCEUTICAL 0009. Another embodiment of the invention provides a COMPOSITIONS composition for chronic skin disorders. It can be used alone or combined with pharmaceuticals, and can be used to treat PRIOR RELATED APPLICATIONS diseases such as psoriasis, dermatitis, skin infections, shingles (herpes Zoster), boils, eczema, rash, acne or burn, 0001. Not applicable. and the like. FEDERALLY SPONSORED RESEARCH STATEMENT DETAILED DESCRIPTION OF THE FIGURES 0002. Not applicable. 0010 FIG. 1 shows representative examples of diabetic foot lesions treated with the herbaria of Table 1. REFERENCE TO MICROFICHEAPPENDIX (0011 FIG. 2 shows representative examples of PCOS treated with the herbaria of Table 2. 0003) Not applicable. 0012 FIG. 3 shows representative examples of psoriasis FIELD OF THE INVENTION treated with the herbaria of Table 3. 0004. The invention relates to phytoceutical formulations DETAILED DESCRIPTION OF THE INVENTION used to treat a variety of diseases. The formulations are par ticular combinations of plants and have synergistic effect in 0013 “Pharmaceutically acceptable excipients' is used combination. Principles for selecting beneficial formulations hereinaccording to art accepted meanings, and includes those are provided. ingredients needed to formulate a medicine for mammalian use, including the use of gelatin capsules. BACKGROUND OF THE INVENTION 0014 “Synergistic' or “synergy” is used herein to mean that the effect is more than its additive property. In preferred 0005. The academic study of medicinal plants for the treatment of diverse diseases has been nearly as pervasive as embodiments, the synergy is at least 1.5, 2, 5, or 10 fold. the study of Western medicines The active principles from 0015. By use of “plants.” what is meant herein is that the many traditional medicines have been extracted from plants, plant (or that portion with medicinal activity) is used whole, the curative agents identified and their mechanisms of action ground, or as an extract. Also included are purified active determined. Plant based medicines are typically well toler ingredients and derivatives thereof. However, it is believed ated, with less severe side effects as well as a smaller range of that the best efficacy of plants used herein is achieved with the side effects. However, despite the excellent medicinal quali use of the entire plant or its extracts, rather than with the use ties of many plants, they are individually insufficient to take of isolated active ingredients. chronic degenerative diseases into remission. In contrast, 0016 Further, although plants are named here according while synthetic drugs can be highly effective, their use is to commonly used nomenclature, with improving taxonomy often hampered by severe side effects. What is needed in the plants are often reclassified. Whenever a plant is referenced, art are better treatment regimes with improved patient toler it includes related species with similar active ingredients. ance, while providing sufficient efficacy. 0017. The following examples are illustrative only and should not serve to unduly limit the invention. SUMMARY OF THE INVENTION 0006. A number of known beneficial plants were classified Example 1 according to their capacity to enhance the three main ele ments that support overall health: Energy (E), Bio-intelli Plant Characteristics Circulatory Disorders gence (I) and Organization (O). A synergistic effect is 0018 Angelica sinensis (Dong Quai or Angelica, also expected when all three categories of herbs (E. I. O) are Angelica Archangelia, Angelica Pubescens and Angelica included in a formulation, preferably at least two or three or Sylvestris) contains terpenes (terpenes, mainly B-phelland four plants from each category. Thus, one embodiment of the rene, with B-bisabolene, B-caryophyllene, B-phellandrene, C.- invention provides a method of selecting additional disease and B-pinene, limonene, linalool, borneol, acetaldehyde, treating formulations according to these principles. Three examples of formulations prepared in this way are provided menthadienes, and nitromenthadienes), macrocyclic lactones and additional formulations are being prepared and tested. (including tridecanolide, 12-methyl tridecanolide, pentade 0007 Another embodiment of the invention provides an canolide), phthalates (such as hexamethylphthalate), cou effective, natural composition for treating circulatory dis marins (especially furocoumarin glycosides such as eases. The composition can be used alone, or can be com marmesin and apterin), angelicin and byakangelicin deriva bined with simultaneous use of one or more pharmaceutical tives (osthol, umbelliferone, psoralen, bergapten, impera compositions. It can be used for the treatment of diabetic toren, XanthotoXol, Xanthotoxin, oxypeucedanin and more), lesions, obliterative arteriosclerosis, Leriche Syndrome as well as various Sugars, plant acids, flavonoids, and sterols. (aorto-iliac obliteration), Buerger's disease (thromboangiitis 0019 Acanthopanax senticosus (Russian Ginseng, Sibe obliterans), thrombophlebitis, chronic venous insufficiency, rian Ginseng, Eleuthero, Devil's Shrub, Touch-me-not, Wild Varicose veins, varicose ulcers, hemorrhoids, and the like. Pepper, Shigoka, Acantopanacis senticosus) contains terpe 0008 Another embodiment of the invention provides a noids (oleanolic acid), glycosides (Eleutheroside A (daucos composition for the treatment offeminine endocrine diseases terin), B1, C-G, I, K, L, M), phytosterols (B-sitosterol), cou that can be used alone or combined with pharmaceuticals. It marins (Eleutheroside B1 and B3, isofraxidine), provides an effective medicine for diseases such as Polycystic polysaccharides (eleutherans), Volatile oils, caffeic acid, Ovary Syndrome, ovarian cysts, fibrocystic breast condition, coniferyl aldehyde, and Sugars. Eleuthero has been shown to uterine fibroids, dysfunctional uterine hemorrhage, female bind to estrogen, progestin, and mineralocorticoid receptors, infertility, premenstrual syndrome, amenorrhea, and the like. and stimulate T-lymphocyte and natural killer cell produc US 2011/0052718A1 Mar. 3, 2011 tion. It has activity anti-plateletaggregation activity similar to pfaffic acids, phytosterols (sitosterol and estimasterol). It also aspirin, as well as antioxidant activity. Russian Ginsengcon contains Saponins. Its germanium content probably accounts tains at least 40 active ingredients. for its properties as an oxygenator at the cellular level, and its 0020 Rhaponticum carthamoides (Leuzea, or Maral high iron content may account for its traditional use for ane Root) contains a mixture of compounds called, “levseins.” mia. This herb increases oxygenation at the cellular level, and LeVSeins represents a complex of more than 10 ecdysterones it also has anabolic activity at the muscular and cardiac levels including 20-beta-ecdysterone, makisterone C, 24-dehydro by improving the contraction of the miocardia and diminish makisterone A, carthamosterone, polypodyne B and ajugas ing arrhythmias and stabilizing the membranes of cardiac terone C. Researchers extracted and purified various ecdys cells. The incorporation of this phytomedicine provides 44 teroids from Rhaponticum and found that the ecdysteroids active principles in a single therapeutic. increased the mass of the developing quails in a dose-depen 0024 Rhodiola rosea (Golden Root, Roseroot) consists dent manner, with the rate of increase proportional to the mainly of phenylpropanoids (rosavin, rosin, rosarin (specific